Author: admin

FG Capital Advisors Broadens Carbon-Focused Investment Program Across the Congo Basin, Highlighting Peatland Conservation and Financial Innovation

LONDON – January 3, 2025 – FG Capital Advisors announces an expanded investment initiative offering corporations and high-net-worth individuals a unique opportunity to finance the redevelopment of historically underutilized mining, oil, and forest sites throughout the Congo Basin. Emphasizing the critical role of peatlands in global climate stability, these projects will adhere to the highest carbon standards — including VCS and REDD+ — while also leveraging blockchain technology for enhanced measurement, reporting, and verification (MRV).

This broader scope follows recent events such as the Democratic Republic of Congo’s cancellation of a licensing round for 27 oil blocks in October 2024. As the Congo Basin spans multiple countries and hosts some of the world’s most carbon-rich peatlands, FG Capital Advisors aims to create viable alternatives that balance regional development with urgent climate goals.

Although the firm itself is relatively new, Founder and Managing Director Kenny Kayembe brings extensive experience in physical commodity trading and mining exploration finance. His established network across government and private sectors—encompassing multiple Congo Basin nations and major commodity firms — enables FG Capital Advisors to navigate local regulations effectively and foster inclusive community partnerships.

Once funding is secured, FG Capital Advisors will:

  • Identify and Acquire Key Sites — including peatlands and forested regions—ideal for carbon sequestration and renewable energy deployment.
  • Assemble Specialized Teams — drawing on expertise in environmental science, engineering, and project development — to ensure viable and impactful projects.
  • Implement Verified Carbon Projects — aligned with best-in-class standards (VCS, REDD+) and subject to third-party audits, satellite-based monitoring, and AI-driven data analytics.

While the firm embraces well-established frameworks like VCS and REDD+, it also deploys blockchain as a complementary layer for MRV, ensuring maximum transparency, preventing double-counting, and reinforcing investor confidence.

Quote from Kenny Kayembe, Founder and Managing Director, FG Capital Advisors “By moving beyond traditional conservation approaches, we’re integrating financial innovation, renewable energy, and strong local partnerships to tackle the most pressing climate challenges in the Congo Basin. Our goal is to generate high-integrity carbon offsets that simultaneously create economic value for surrounding communities. We see this as the path to transforming potential into impact — and once investors witness the caliber of these projects, we expect even greater momentum.”

A Carbon Token offering is planned for late 2025, providing an additional avenue for investors to realize returns on verified credits. In the interim, FG Capital Advisors will operate through a conventional project-finance model, deploying capital directly into site acquisition, project development, and ongoing oversight.

For more information, please visit fgcapitaladvisors.com/voluntary-carbon-markets-token or contact:

FG Capital Advisors, contact@fgcapitaladvisors.com, Attn: Kenny Kayembe

Media Contact
Company Name: FG Capital Advisors
Contact Person: Kenny Kayembe
Email: Send Email
Country: United Kingdom
Website: fgcapitaladvisors.com/voluntary-carbon-markets-token

Smoking Cessation and Nicotine Addiction Therapeutics Market Size in the 7MM was ~USD 2,318 Million in 2023 and is projected to increase by 2034 and estimated DelveInsight

DelveInsight’s “Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Smoking Cessation and Nicotine Addiction, historical and forecasted epidemiology as well as the Smoking Cessation and Nicotine Addiction market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Discover Key Insights into the Smoking Cessation and Nicotine Addiction Market with DelveInsight’s In-Depth Report @ Smoking Cessation and Nicotine Addiction Market Size

 

Key Takeaways from the Smoking Cessation and Nicotine Addiction Market Report

  • According to DelveInsight estimates, EU4 and the UK accounted for approximately 63,953 thousand cases, which was the highest prevalent cases of tobacco use, followed by the US with around 50,886 thousand cases, and Japan with around 20,185 thousand cases in 2023. These cases are expected to decrease in the US, EU4 the UK, and Japan by 2034.
  • Among the EU4 and the UK, Germany had the highest prevalent cases of tobacco use (approximately 18,101 thousand cases), followed by France (approximately 16,429 thousand cases) in 2023. On the other hand, the UK (8,788 thousand cases) had the lowest prevalent cases of tobacco use in EU4 and the UK countries and the 7MM.
  • Tobacco use has been identified as male-dominant; in our analysis, the number of males suffering was higher than females. In 2023, ~59% of prevalent cases tobacco use of were of males, while ~41% of cases were of females in the 7MM.
  • The leading Smoking Cessation and Nicotine Addiction Companies such as Achieve LifeSciences, NFL Biosciences SAS, Embera Neuro Therapeutics Inc., Axsome Therapeutics, Currax Pharmaceuticals LLC, Omeros Corporation, Promentis Pharmaceuticals, Otsuka Pharmaceutical, and others.
  • Promising Smoking Cessation and Nicotine Addiction Pipeline Therapies such as NicVAX vaccine, Varinecline (Chantix), Cytisine, Nicotine Replacement Therapy (NRT), Liraglutide, Bupropion, and others.

 

Stay ahead in the Smoking Cessation and Nicotine Addiction Therapeutics Market with DelveInsight’s Strategic Report @ Smoking Cessation and Nicotine Addiction Market Outlook

 

Smoking Cessation and Nicotine Addiction Epidemiology Segmentation in the 7MM

  • Prevalent Cases of Tobacco Use
  • Gender-specific Prevalent Cases of Tobacco Use
  • Age-specific Prevalent Cases of Tobacco Use
  • Prevalent Cases of Tobacco Use by Product Type
  • Prevalent Nicotine Dependent Cases Among Cigarette Smokers
  • Prevalent Cases of Smoking Cessation

 

Download the report to understand which factors are driving Smoking Cessation and Nicotine Addiction Epidemiology trends @ Smoking Cessation and Nicotine Addiction Prevalence

 

Smoking Cessation and Nicotine Addiction Marketed Drugs

 

  • CHANTIX/ CHAMTIX (varenicline): Pfizer

CHANTIX, known chemically as varenicline tartrate, is a nicotinic receptor partial agonist used as an aid for smoking cessation. Unlike nicotine replacement therapies, CHANTIX works by blocking the pleasurable effects of smoking and reducing cravings and withdrawal symptoms. The US FDA approved varenicline in May 2006 as the first oral non-nicotine smoking cessation treatment. It has also been approved in the EU4, the UK, and Japan for the same purpose. In May 2007, Pfizer announced that NICE recommended CHAMTIX (varenicline) for use in the UK’s National Health Service for adult smokers wishing to quit. In August 2021, the FDA approved the first generic version of CHANTIX, developed by Par Pharmaceutical, offering 0.5 mg and 1 mg tablets. This milestone provides a more accessible option for individuals seeking to overcome nicotine addiction.

 

  • ZYBAN (bupropion): GlaxoSmithKline

ZYBAN (bupropion hydrochloride) sustained-release tablets are a non-nicotine aid for smoking cessation. Chemically unrelated to nicotine or other treatments for nicotine addiction, ZYBAN was initially developed as an antidepressant under the names WELLBUTRIN and WELLBUTRIN SR. Bupropion is a selective inhibitor of the neuronal reuptake of catecholamines (noradrenaline and dopamine) with minimal effect on serotonin reuptake, and it does not inhibit monoamine oxidase. The precise mechanism by which ZYBAN aids in smoking cessation is unclear but is believed to involve noradrenergic and/or dopaminergic pathways. Initially introduced in 1989 as an antidepressant, bupropion was later produced in a sustained-release (SR) formulation in 1996. Its smoking cessation properties were identified in 1997, leading to its recognition as a first-line anti-smoking agent in the US and UK. In May 2010, Mylan Pharmaceuticals received FDA approval for a generic version of ZYBAN, providing a cost-effective option for those seeking to quit smoking.

 

Smoking Cessation and Nicotine Addiction Emerging Drugs

 

  • Cytisinicline (cytisine): Achieve Life Sciences

Cytisinicline (cytisine) is an oral, plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment approved and marketed in Central and Eastern Europe for over 20 years. Cytisinicline has completed a Phase III study, evaluating the efficacy and safety of 3 mg cytisinicline thrice a day for a treatment duration of 42 days/6 weeks in adult smokers cytisinicline. In addition to this trial, the company is conducting another Phase III study, ORCA-OL, which is in progress as per the company’s pipeline. Achieve Life Sciences is also evaluating cytisinicline in Phase II for the e-cigarette user population.

 

  • NFL-101: NFL Biosciences SAS

NFL-101, a patented botanical drug candidate, aims to improve smoking cessation rates. It involves two subcutaneous injections one week apart, with optional injections at three and six months if needed. A Phase I/II trial confirmed its safety and efficacy for long-term cessation without compensatory smoking. Unlike varenicline (Chantix/Champix) and nicotine replacement therapies, NFL-101 contains minimal nicotine and is derived from natural tobacco leaf proteins. In February 2023, NFL Biosciences collaborated with the CEA to study NFL-101’s mechanism using molecular imaging. In November 2021, they partnered with Diverchim to develop GMP-compliant active ingredients for NFL-101 and NFL-201 for treating tobacco and cannabis addiction. This supports the production of essential components for the CESTO II (Phase II/III) clinical study. Results from the Phase IIb efficacy study (CESTO 2) are expected in July 2024.

 

  • EMB-001: Embera NeuroTherapeutics, Inc.

EMB-001, a patented combination of metyrapone and oxazepam, targets the stress response system to address addiction and relapse by reducing stress-induced cravings and loss of control. It aims to maximize efficacy by affecting multiple pathways and promoting long-term abstinence across various addictions. In 2019, Embera NeuroTherapeutics received substantial grants to advance EMB-001 into Phase II clinical studies for cocaine use disorder and smoking cessation. The National Institute on Drug Abuse (NIDA) provided part of a USD 11.1 million grant for a Phase II study on cocaine use disorder, while the Rose Research Center (RRC) in North Carolina received funding to evaluate EMB-001 for smoking cessation, supported by the Foundation for a Smoke-Free World. In the nicotine study, EMB-001 also demonstrated a statistically significantly greater effect relative to varenicline (CHANTIX), the clinical market leader for smoking cessation efficacy.

 

Get In-Depth Knowledge on Smoking Cessation and Nicotine Addiction Market Trends and Forecasts with DelveInsight @ Smoking Cessation and Nicotine Addiction Treatment Market

 

Smoking Cessation and Nicotine Addiction Market Outlook

There are effective treatments that support tobacco cessation, including both behavioral therapies and FDA-approved medications. Several distinct products and services are available today for smoking cessation, alongside smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapies (NRTs) in the form of transdermal patches, gums, nasal sprays, oral inhalers, and lozenges.

 

Scope of the Smoking Cessation and Nicotine Addiction Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Smoking Cessation and Nicotine Addiction Companies- Achieve LifeSciences, NFL Biosciences SAS, Embera Neuro Therapeutics Inc., Axsome Therapeutics, Currax Pharmaceuticals LLC, Omeros Corporation, Promentis Pharmaceuticals, Otsuka Pharmaceutical, and others.
  • Smoking Cessation and Nicotine Addiction Pipeline Therapies- NicVAX vaccine, Varinecline (Chantix), Cytisine, Nicotine Replacement Therapy (NRT), Liraglutide, Bupropion, and others.
  • Smoking Cessation and Nicotine Addiction Therapeutic Assessment: Smoking Cessation and Nicotine Addiction current marketed and Smoking Cessation and Nicotine Addiction emerging therapies
  • Smoking Cessation and Nicotine Addiction Market Dynamics: Smoking Cessation and Nicotine Addiction market drivers and Smoking Cessation and Nicotine Addiction market barriers
  • Smoking Cessation and Nicotine Addiction Unmet Needs, KOL’s views, Analyst’s views, Smoking Cessation and Nicotine Addiction Market Access and Reimbursement

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Smoking Cessation and Nicotine Addiction Market Report @ Smoking Cessation and Nicotine Addiction Market Drivers and Barriers

 

Table of Content

1 Key Insights

2 Report Introduction

3 Smoking Cessation and Nicotine Addiction Market Overview at a Glance

4 Epidemiology and Market Forecast Methodology

5 Key Events

6 Executive Summary of Smoking Cessation and Nicotine Addiction

7 Smoking Cessation and Nicotine Addiction: Disease Background and Overview

8 Epidemiology and Patient Population of Smoking Cessation and Nicotine Addiction

9 Patient Journey

10 Marketed Drugs

11 Emerging Drugs

12 Smoking Cessation and Nicotine Addiction: Seven Major Market Analysis

13. Market Size of Smoking Cessation and Nicotine Addiction in Japan

14 Key Opinion Leaders’ View

15 SWOT Analysis

16 Unmet needs

17 Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smoking Cessation and Nicotine Addiction Therapeutics Market Size in the 7MM was ~USD 2,318 Million in 2023 and is projected to increase by 2034 and estimated DelveInsight

Sepsis Therapeutics Market Size in the 7MM is expected to grow by 2034, estimated DelveInsight

DelveInsight’s “Sepsis Drugs Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Sepsis, historical and forecasted epidemiology as well as the Sepsis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Discover Key Insights into the Sepsis Market with DelveInsight’s In-Depth Report @ Sepsis Market Size

 

Key Takeaways from the Sepsis Market Report

  • In December 2024: Basilea Pharmaceuticals- This study will evaluate the safety, pharmacokinetics and efficacy of ceftobiprole in term and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS). Ceftobiprole is an antibiotic which belongs to a group of medicines called ‘cephalosporin antibiotics’. It is approved for its use to treat adults and children with pneumonia in many European and non-European countries.
  • In December 2024:- Novartis Pharmaceuticals- The purpose of this Ph2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).
  • Among 7MM, the United States accounted for the maximum share of the Sepsis population with above 55% in 2023.
  • In EU4 and the UK, Germany accounted for the highest number of incident cases in 2023.
  • As per analysis, it is notable that in the 7MM, the majority of patient pool were males as compared to females whereas in the US female population dominated the Sepsis incident pool..
  • According to Delveinsight, approximately 57% of all cases were sepsis without organ dysfunction followed by septic shock (24%) and severe sepsis (18%) in the United States in 2023. These cases are expected to increase during the forecast period (2024-2034).
  • As per the analysis, lung infection, UTI infection, gut infection, and skin infection are the leading four infection sites in patients with sepsis, accounting for approximately 43%, 30%, 13%, and 13% respectively of all sites of infection.
  • The leading Sepsis Companies such as La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.
  • Promising Sepsis Pipeline Therapies such as Alirocumab, Imipenem, Cilastatin and Relebactam, Cefiderocol, SBI-101, Ceftobiprole medocaril, VBI-S, and others.

 

Stay ahead in the Sepsis Therapeutics Market with DelveInsight’s Strategic Report @ Sepsis Market Outlook

 

Sepsis Epidemiology Segmentation in the 7MM

  • Total Sepsis Incident cases
  • Sepsis Gender-specific Incident cases
  • Sepsis Severity-specific Incident Cases
  • Sepsis Origin-specific Incident cases

 

Download the report to understand which factors are driving Sepsis epidemiology trends @ Sepsis Prevalence

 

Sepsis Marketed Drugs

 

  • GIAPREZA (angiotensin II): La Jolla Pharmaceuticals/Innoviva Specialty Therapeutics

GIAPREZA (angiotensin II) (La Jolla Pharmaceuticals/Innoviva Specialty Therapeutics) injection is approved by the US FDA in December 2017 as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shocks. The drug is also approved by the European Commission in 2019 to treat refractory hypotension in adults with septic or other distributive shocks who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. The drug mimics the body’s endogenous angiotensin II peptide, which is central to the renin–angiotensin–aldosterone system, which regulates blood pressure.

 

  • Onoact Injection (Landiolol hydrochloride): Ono Pharmaceuticals

Onoact is a short-acting β1 blocker that selectively blocks β1 receptors mainly found in the heart. It is for emergency treatment of intra-operative or post-operative tachyarrhythmia (atrial fibrillation, atrial flutter, sinus tachycardia) and treatment of tachyarrhythmia in left ventricular dysfunction (atrial fibrillation, atrial flutter). In June 2022, Onoact received approval for intravenous infusion 50mg/150mg, for the additional indication of tachyarrhythmia (atrial fibrillation, atrial flutter, and sinus tachycardia) associated with sepsis for a partial change in the approved items of the manufacturing and marketing approval in Japan.

 

Sepsis Emerging Drugs

 

  • VBI-S: Vivacelle Bio

Vivacelle Bio’s lead candidate, VBI-S is made of small particles of specific lipid called micelles and liposomes to treat hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the ’body’s fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. In July 2019, the company announced US FDA clearance to enroll patients into a Phase IIa clinical trial of VBI-S to elevate blood pressure in subjects who have shock due to sepsis, later met 100% endpoints in Phase II. The therapy is currently under Phase III clinical evaluation to treat hypovolemia due to sepsis/septic shock.

 

  • Nangibotide: Inotrem

Inotrem’s Nangibotide is a synthetic peptide and first-in-class TREM-1 inhibitor. Nangibotide blocks the TREM-1-mediated immune dysregulations in sterile or infectious acute inflammatory syndromes. The drug restores a balanced inflammatory response and improves outcomes, particularly in those patients with high levels of TREM-1 pathway activation. The drug is currently under Phase II for the treatment of septic shock. This lead candidate has been granted EMA’s PRIority MEdicines (PRIME) scheme, and was also granted Fast-track status by the FDA for septic shock.

 

Get In-Depth Knowledge on Sepsis Market Trends and Forecasts with DelveInsight @ Sepsis Treatment Market

 

Sepsis Market Outlook

Sepsis is a complex disease, which not only involves a wide array of causative agents but also results in different individual immune responses, causing various single or multiple organ dysfunction. Treatment for sepsis varies, depending on the site and the cause of the initial infection, the organs affected and the extent of any damage. Sepsis should be treated as a medical emergency and treated as quickly and efficiently as possible as soon as it has been identified.

 

Sepsis Drugs Market

The Sepsis Therapeutics Market in the 7MM is anticipated to grow significantly between the forecasted period [2024-2034], driven by factors such as increasing Sepsis Incidence rates, technological advancements, enhanced funding for drug development, heightened public awareness, and expanding research endeavors. The expected launch of emerging therapies, combined with the rise in Sepsis cases, is poised to fuel market expansion throughout the forecast period. The promising pipeline for Sepsis presents a hopeful outlook for improved treatment modalities in the years ahead.

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Sepsis Market Report @ Sepsis Market Drivers and Barriers

 

Scope of the Sepsis Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Sepsis Companies- La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.
  • Sepsis Pipeline Therapies- Alirocumab, Imipenem, Cilastatin and Relebactam, Cefiderocol, SBI-101, Ceftobiprole medocaril, VBI-S, and others.
  • Sepsis Therapeutic Assessment: Sepsis current marketed and Sepsis emerging therapies
  • Sepsis Market Dynamics: Sepsis market drivers and Sepsis market barriers
  • Sepsis Unmet Needs, KOL’s views, Analyst’s views, Sepsis Market Access and Reimbursement

 

Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Key Events

5 Epidemiology and Market Forecast Methodology

6 Sepsis Market Overview at a Glance

7 Sepsis: Disease Background and Overview

8 Treatment and Medical Management

9 Epidemiology and Patient Population of Sepsis

10 Patient Journey

11 Marketed Drugs

12 Key Cross Competition

14 Sepsis: Seven Major Market Analysis

15 KOL Views

16 SWOT Analysis

17 Unmet Needs

18 Market Access and Reimbursement

19 Appendix

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sepsis Therapeutics Market Size in the 7MM is expected to grow by 2034, estimated DelveInsight

L.P. Simone’s Charlotte’s Ghosts: The Mystery of the Vanishing Boy is a Compelling Work of Middle-Grade Fiction That Explores Love and Loss Across Centuries

Charlotte’s Ghosts: The Mystery of the Vanishing Boy by L.P. Simone intricately weaves together the lives of Charlotte, a young girl dealing with the loss of her father, and Jeremy, a fallen Civil War soldier, who are separated by time but connected by fate as they navigate different challenges in a poignant tale of love, loss and friendship.

L.P. Simone is a multiple award-winning author and blogger. She has published two novels: Charlotte’s Ghosts: The Mystery of the Vanishing Boy and The 2012 Prophecies: Heir of the Jaguar, compelling works of middle-grade fiction that have been honored with numerous international literary awards including a Literary Titan Book Award, an American Legacy Book Award, a Feathered Quill Book Award, and a Next Generation Indie Book Award.

A voracious reader, L.P. also has two book blogs: Liv4MGlit and Liv4YAlit, where she shares reviews of books for young people.

L.P. earned a Master’s Degree in Latin American Studies from Georgetown University and a Masters’ Degree in Writing for Children and Young Adults from the Vermont College of Fine Arts. She worked as a school librarian in Washington, DC where she also taught History and Writing, and taught English in Guatemala.

Today, she lives and writes in Washington, DC.

This one-on-one interview shares Simone’s background and experience writing Charlotte’s Ghosts: The Mystery of the Vanishing Boy.

Tell us about Charlotte’s Ghosts: The Mystery of the Vanishing Boy.

Charlotte’s Ghosts: The Mystery of the Vanishing Boy is a dual voice novel for middle grade readers that explores the bonds of love that persist even beyond death.

The spring before 7th Grade, Charlotte tragedy strikes. Dad won’t be coming home from Afghanistan. Her mother packs her up and moves her across the country to Manassas, Virginia, to a new neighborhood, a new school, and a new life, one without her mighty, fearless, beloved father.On the Civil War battlefield near her home, she meets Jeremy, the ghost of a young Union soldier. When Jeremy disappears right before her eyes, Charlotte knows, somehow, she must help him find peace.  Through her efforts to help Jeremy, she begins to finally face her own loss.Jeremy’s story unfolds in alternate passages. In 1861 when the Confederacy secedes, Jeremy Turner wants nothing more than to join Lincoln’s army and shoot himself some Rebels, if only his mother would sign the enlistment papers. He abandons his family farm and leaves behind everything he loves, before finding his way into the bloodiest war in American history.

Readers explore Charlotte and Jeremy’s individual journeys, witnessing both their challenges and their discoveries. Ultimately, Charlotte helps Jeremy find his way home, and she begins to realize that her father’s love lives on in her, because those we truly love are never truly gone. 

What inspired you to write Charlotte’s Ghosts: The Mystery of the Vanishing Boy?

Visiting a Civil War battlefield turned park near me, I felt overwhelmed by the thought that thousands of soldiers died on the very ground where I stood. I found myself grieving for them as well as those they left behind.

I lost my mother at 13, so I know intimately what it’s like to lose a parent as a young person. 

I wrote Charlotte’s Ghosts as a way to examine my own journey through sorrow and to support those who are experiencing loss. In reading the book, my hope is for readers to understand that love’s bonds do not break, despite the pain we feel when someone we love is gone.

In the words of Hellen Keller, “All that we love deeply becomes a part of us.” 

How did your background and experience influence your writing?

As a young person, before the internet and smartphones, or hand-held games, I spent many long car rides escaping into books or inventing characters and stories of my own.

Then after earning a Masters’ Degree in Writing for Children and Young Adults from Vermont College of Fine Arts, I found a way to explore my own grief and longing by writing Charlotte’s Ghosts.

What is one message you would like readers to remember?

Love lives on, even when those we love are gone forever.

Purchasing the Book

Charlotte’s Ghosts: The Mystery of the Vanishing Boy has received favorable reviews from well-known literary organizations, authors, and reviewers around the world. Book Excellence writes, “Charlotte’s Ghosts is a gripping adventure where the past and present collide in a tale of loss, friendship, and a touch of the supernatural.” In addition, Booklife writes, “A cozy contemporary paranormal mystery offers an opportunity for a gentle historical perspective on war and loss in this time-crossed middle grade novel.”

The book is available for sale on Amazon, Google Play, and other online bookstores. Readers are encouraged to purchase their copy today: https://www.amazon.com/Charlottes-Ghosts-Mystery-Vanishing-Boy-ebook/dp/B0C77VVTX2 

To connect with L.P. and learn more about her work, visit: www.dragonsongpublishing.com. You can also find her on Facebook and Instagram.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: L.P. Simone’s Charlotte’s Ghosts: The Mystery of the Vanishing Boy is a Compelling Work of Middle-Grade Fiction That Explores Love and Loss Across Centuries

Focal Segmental Glomerulosclerosis Therapeutics Market Size in the 7MM was ~USD 734 million in 2022, is expected to grow by 2034, and estimated DelveInsight

DelveInsight’s “Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology and the FSGS market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Discover Key Insights into the Focal Segmental Glomerulosclerosis Market with DelveInsight’s In-Depth Report @ Focal Segmental Glomerulosclerosis Market Size

 

Key Takeaways from the Focal Segmental Glomerulosclerosis Market Report

  • In December 2024:- Astellas Pharma Global Development, Inc.- The purpose of this study was to assess the efficacy of the bleselumab regimen (basiliximab induction, tacrolimus, steroids and bleselumab) compared with the Standard of Care (SOC) regimen (basiliximab induction, tacrolimus, steroids and mycophenolate mofetil [MMF]) in the prevention of recurrent Focal Segmental Glomerulosclerosis (rFSGS) defined as nephrotic range proteinuria with protein-creatinine ratio (≥ 3.0 g/g) through 3 months post-transplant. Death, graft loss or lost to follow-up were imputed as rFSGS.
  • In December 2024:- Sanofi- A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD).
  • The overall count of individuals diagnosed with Focal Segmental Glomerulosclerosis in the United States was approximately 26 million in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
  • Among the 7MM, Japan accounted for the highest number of Focal Segmental Glomerulosclerosis diagnosed cases of around 8 million cases in 2022. Forecasts indicate a projected increase in the cases during the period (2023-2034).
  • Among EU4 and the UK, Germany had the highest Focal Segmental Glomerulosclerosis diagnosed prevalent population, with about 5 million cases, followed by France and Italy in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
  • In 2022, DelveInsight’s analysis of Focal Segmental Glomerulosclerosis gender-specific diagnosed prevalent cases within the 7MM indicated an approximate distribution of 40% in males and 60% in females.
  • The leading Focal Segmental Glomerulosclerosis Companies such as Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company and others.
  • Promising Focal Segmental Glomerulosclerosis Therapies such as DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others.

 

Stay ahead in the Focal Segmental Glomerulosclerosis Therapeutics Market with DelveInsight’s Strategic Report @ Focal Segmental Glomerulosclerosis Market Outlook

 

Focal Segmental Glomerulosclerosis Epidemiology Segmentation in the 7MM

  • Total Focal Segmental Glomerulosclerosis Diagnosed Prevalent Cases
  • Focal Segmental Glomerulosclerosis Gender-specific Cases
  • Diagnosed Prevalent Cases
  • Focal Segmental Glomerulosclerosis Age-specific Diagnosed Prevalent Cases
  • Focal Segmental Glomerulosclerosis Comorbodity-specific Diagnosed Prevalent Cases

 

Download the report to understand which factors are driving Focal Segmental Glomerulosclerosis Epidemiology trends @ Focal Segmental Glomerulosclerosis Prevalence

 

Focal Segmental Glomerulosclerosis Marketed Drugs

  • LEQVIO (Inclisiran): Novartis Pharmaceuticals Corporation

LEQVIO (Inclisiran) is a sole small-interfering RNA (siRNA) therapy designed to lower LDL cholesterol. The drug utilizes the RNA interference mechanism and directs the catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation. LEQVIO, the sole approved FSGS treatment in United States and Europe with an active patent, dominates the FSGS treatment landscape, immune to biosimilar competition.

 

Focal Segmental Glomerulosclerosis Emerging Drugs

  • Olpasiran (AMG 890): Amgen Inc.

Olpasiran (AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a). It is being investigated for treating FSGS; the drug is administered subcutaneously as a solution. Olpasiran is currently in Phase III clinical trial in participants with FSGS and elevated lipoprotein (a). The absence of approved alternatives highlights the potential for Olpasiran to contribute significantly to the expansion of the FSGS treatment market.

 

Focal Segmental Glomerulosclerosis Market Outlook

Focal Segmental Glomerulosclerosis (FSGS), encompassing diverse conditions like CAD, PAD, and cerebrovascular disease, all rooted in atherosclerosis. FSGS is influenced by genetic predisposition, lifestyle factors, and comorbidities. Strategies vary depending on the severity of the disease, aiming to curb FSGS. Treatment for FSGS starts with a change in lifestyle that includes stress management, regular exercise, dietary adjustments, and quitting smoking. Their potential to supplement pharmaceutical therapies and effectively lower cardiovascular risk factors is highlighted by a thorough examination of their influence on patient outcomes.

Get In-Depth Knowledge on Focal Segmental Glomerulosclerosis Market Trends and Forecasts with DelveInsight @ Focal Segmental Glomerulosclerosis Treatment Market

 

Focal Segmental Glomerulosclerosis Treatment Market

As the Focal Segmental Glomerulosclerosis Treatment Market Landscape evolves, the emergence of Olpasiran in a Phase III trial brings hope for a targeted therapeutic option. The projected introduction of Olpasiran for FSGS is anticipated to propel the overall FSGS market in the 7MM, potentially reaching nearly USD 837 million by 2034.

 

Scope of the Focal Segmental Glomerulosclerosis Market Report

  • Coverage- 7MM
  • Study Period- 2020-2034
  • Focal Segmental Glomerulosclerosis Companies- Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company and others.
  • Focal Segmental Glomerulosclerosis Therapies- DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others.
  • Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
  • Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers
  • Focal Segmental Glomerulosclerosis Unmet Needs, KOL’s views, Analyst’s views, Focal Segmental Glomerulosclerosis Market Access and Reimbursement

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Focal Segmental Glomerulosclerosis Market Report @ Focal Segmental Glomerulosclerosis Market Drivers and Barriers

 

Table of Content

1 Key Insights

2 Report Introduction

3 Focal Segmental Glomerulosclerosis (FSGS) Market Overview by Therapies

4 Methodology of FSGS Epidemiology and Market

5 Executive Summary of Focal Segmental Glomerulosclerosis (FSGS)

6 Key Events

7 Disease Background and Overview: FSGS

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Drugs

11 Emerging Drugs

12 FSGS: Market Analysis

13 Key Opinion Leaders’ Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Focal Segmental Glomerulosclerosis Therapeutics Market Size in the 7MM was ~USD 734 million in 2022, is expected to grow by 2034, and estimated DelveInsight

Andorra’s Business Sector Benefits from Financh’s Comprehensive Company Profiles and Financial Reports

“Businesses in Andorra now have access to tools that were once the domain of multinational corporations. With Financh, they can leverage company financial reports, track competitor performance, and ensure corporate compliance with unparalleled ease. Our mission is to democratize company intelligence and make it accessible to companies of all sizes,” said MD Sadique Akhter, CEO and President of Financh.”
Andorra’s dynamic business sector is leveraging Financh’s cutting-edge platform, which provides comprehensive company profiles, financial reports, and market intelligence tools. By offering private company data, M&A activity insights, and competitor analysis, Financh empowers businesses, investors, and startups in Andorra to drive growth, ensure compliance, and stay ahead in competitive markets.

The bustling business community of Andorra has found a new ally in Financh, a global leader in company intelligence and private company data. With its vast repository of Andorra company financial reports, and advanced market intelligence tools, Financh is equipping businesses in the region with the insights they need to excel in a rapidly evolving economic landscape.

Andorra, known for its strategic location and burgeoning business ecosystem, has long sought ways to streamline corporate operations and expand economic opportunities. Financh’s suite of tools and services now offers a critical solution for businesses to navigate the complexities of today’s market. By providing access to Andorra private company data, competitor analysis, funding and investment data, and comprehensive industry insights, Financh is reshaping the way Andorran businesses approach decision-making and strategy.

Empowering Andorran Businesses with Data and Insights

At the core of Financh’s value proposition are Andorra company profiles and analysis. Covering over 400 million private and listed companies across 185 countries and 250 industries, Financh’s platform offers unmatched depth and breadth of data. These profiles include essential financial information, such as turnover, revenue, profitability, income statements, and balance sheets, alongside market analysis and competitor evaluation.

Streamlining Corporate Compliance and Risk Mitigation

Corporate compliance checks are a critical aspect of Financh’s offerings. With regulatory environments becoming increasingly stringent, Andorran businesses are using Financh’s tools to stay compliant with international standards. By providing detailed company profiles, Financh enables businesses to perform thorough due diligence on partners, vendors, and competitors, reducing risks and ensuring transparency across supply chains.

Supporting Startups and Entrepreneurs

Andorra’s startup ecosystem is also benefiting significantly from Financh’s resources. The platform’s startup directories provide a comprehensive overview of emerging businesses, their funding activity reports, and investor profiles. Entrepreneurs can identify potential partners, secure funding, and benchmark their performance against industry leaders using Financh’s competitive benchmarking tools.

“For startups, access to accurate and timely data can be the difference between success and failure. Financh provides the clarity and insights they need to navigate funding rounds and secure investment,” added Sadique. “Our venture capital trends data and deal sourcing platforms have been instrumental in connecting startups with the right investors.”

Insights into M&A Activity and Market Trends

Mergers and acquisitions (M&A) activity is another area where Financh excels. By offering comprehensive data on global and regional M&A transactions, the platform helps Andorran businesses identify opportunities and craft strategies for growth. With insights into deal types, valuations, and sector-specific trends, Financh enables businesses to approach M&A with confidence and precision.

The platform’s funding and investment data further complement these capabilities, providing a clear view of market trends and helping businesses make informed decisions. From private equity firms to corporate strategy teams, users can access detailed reports on funding activity, supply chain insights, and market dynamics.

Driving Business Performance and Competitive Benchmarking

For established businesses in Andorra, Financh’s company performance tracking and business scores offer a robust framework for evaluating growth and profitability. Through advanced financial analytics and benchmarking tools, companies can measure their performance against industry standards and identify areas for improvement.

“Competitive benchmarking is not just about knowing where you stand; it’s about understanding how to improve,” said Sadique. “Our tools empower businesses to set realistic goals, monitor progress, and stay ahead of the competition.”

A Trusted Resource for Investors and Analysts

Investors in Andorra are also leveraging Financh’s extensive database to identify high-potential opportunities. The platform’s market intelligence tools, combined with detailed investor profiles and funding activity reports, provide a holistic view of the private capital ecosystem. Whether analyzing venture capital trends or evaluating supply chain insights, investors can make data-driven decisions that align with their strategic objectives.

Shaping the Future of Andorra’s Business Landscape

As Andorra continues to attract international attention for its pro-business policies and strategic location, Financh is poised to play a pivotal role in the region’s economic growth. By offering cutting-edge tools for company profiles and analysis, corporate compliance checks, and competitive benchmarking, Financh is enabling businesses to thrive in an increasingly interconnected world.

“Our commitment to innovation and excellence drives everything we do,” concluded Sadique. “We are proud to support Andorra’s business community with the insights and tools they need to succeed.”

For more information about Financh and its offerings, visit https://financh.org.

 

Media Contact
Company Name: Financh
Contact Person: Press Team
Email: Send Email
Address:447 Broadway, 1137, 2nd Floor
State: New York
Country: United States
Website: https://financh.org/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Andorra’s Business Sector Benefits from Financh’s Comprehensive Company Profiles and Financial Reports

AMBCrypto CEO on Sustainable Practices in Crypto Mining

“Renewable energy elements like solar panels and wind turbines integrated with digital blockchain nodes symbolize the harmony between innovation and environmental responsibility in crypto mining.”
Himanshu Kumar, CEO of AMBCrypto, outlines strategies for sustainable crypto mining, emphasizing renewable energy, energy-efficient algorithms, and community-led initiatives. Highlighting innovations like heat recycling and blockchain transparency, he advocates for balancing growth with environmental stewardship to create a greener future for the crypto industry.

The Environmental Impact of Crypto Mining

Crypto mining has drawn significant criticism for its environmental footprint. With rising energy consumption and growing scrutiny from environmental groups, sustainable practices are no longer optional. Himanshu Kumar, CEO of AMBCrypto, addresses the need for eco-friendly mining solutions that balance innovation with environmental stewardship. “The crypto industry must lead by example in addressing its ecological challenges,” he asserts.

Mining operations worldwide consume vast amounts of energy, comparable to the electricity usage of small nations. This has led to a pressing demand for sustainable solutions to mitigate environmental damage while supporting the rapid growth of blockchain technology.

Transitioning to Renewable Energy

Renewable energy sources are reshaping the mining landscape. Kumar notes, “Innovative mining firms are harnessing solar, wind, and hydroelectric power to reduce carbon emissions.”

Solar farms in sunny regions and hydroelectric plants in areas with abundant water resources are becoming popular choices for mining facilities. These renewable options not only reduce the industry’s carbon footprint but also lower operational costs in the long term. “Mining powered by renewables is a win-win solution for the industry and the planet,” Kumar emphasizes.

Countries like Iceland and Canada, with their natural geothermal and hydroelectric resources, have emerged as leaders in sustainable mining practices. Kumar points out that these locations demonstrate how renewable energy can make crypto mining more efficient and environmentally friendly.

The Role of Energy-Efficient Algorithms

The shift towards energy-efficient algorithms is another crucial development. Proof-of-Stake (PoS) and similar consensus mechanisms are gaining traction as alternatives to the energy-intensive Proof-of-Work (PoW) model. “Ethereum’s transition to PoS is a milestone in making crypto mining more sustainable,” Kumar remarks.

PoS significantly reduces the energy required for network operations, relying on validators instead of miners to maintain the blockchain. Kumar believes that adopting such models across other cryptocurrencies could dramatically lower the industry’s overall energy consumption. “The industry’s future lies in embracing innovation that prioritizes efficiency without compromising security,” he adds.

Geographical Shifts in Mining

Regions with abundant renewable energy, like Scandinavia and Canada, are emerging as mining hubs. Kumar highlights, “These regions offer both cost-effective and sustainable energy solutions for miners.”

The geographical shift in mining operations is driven by the search for low-cost, renewable energy sources. Scandinavia’s surplus wind and hydropower, coupled with its cool climate, provides an ideal environment for crypto mining. Similarly, Canada’s hydroelectric plants and progressive energy policies attract large-scale mining operations seeking sustainability.

Kumar underscores the importance of this trend, noting that geographical diversification reduces the risk of centralization while promoting eco-friendly practices globally.

Recycling Heat for a Greener Future

Innovative practices, such as heat recycling, are adding to sustainability in mining. Mining operations generate significant amounts of heat, often wasted. However, forward-thinking companies are repurposing this heat for agricultural and industrial uses. Kumar states, “This not only optimizes energy use but also demonstrates how mining can contribute to local economies.”

For example, some mining facilities channel excess heat to greenhouses, fostering year-round agriculture in colder regions. Others provide heating for residential or commercial buildings. These initiatives showcase how the industry can turn a byproduct of mining into a resource, creating shared value for surrounding communities.

Community-Led Initiatives

Community-driven mining initiatives are setting new standards for sustainability and inclusivity. These projects focus on sustainable practices and benefit-sharing models. “Collaboration between communities and miners can redefine the industry’s image,” Kumar adds.

By involving local stakeholders, these initiatives ensure that mining operations align with community needs and environmental goals. Kumar highlights examples where mining revenues are reinvested in local infrastructure, education, and renewable energy projects. “When the community prospers alongside the industry, it creates a more sustainable and ethical mining ecosystem,” he explains.

Leveraging Technology for Monitoring and Efficiency

Advanced technologies are playing a crucial role in making mining more sustainable. AI-driven systems monitor energy usage and optimize mining operations in real-time. Kumar emphasizes, “Harnessing data and automation can significantly improve efficiency, reduce waste, and lower costs.”

Blockchain itself offers solutions for transparency in energy usage. Kumar suggests that integrating smart contracts to track and verify renewable energy sources can set new benchmarks for accountability in the industry.

Conclusion: Building a Sustainable Future

Sustainability in crypto mining is achievable with the right strategies. Kumar envisions an industry where innovation and environmental responsibility go hand in hand. “It’s time for the crypto industry to align its practices with global sustainability goals and lead by example,” he concludes.

As mining operations continue to expand, Kumar calls for industry-wide collaboration to address environmental concerns. “The future of blockchain depends on our ability to create systems that are not just profitable but also sustainable and equitable for all stakeholders.”

Media Contact
Company Name: AMBCrypto
Contact Person: Sujeev Thomas
Email: Send Email
Country: India
Website: https://ambcrypto.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AMBCrypto CEO on Sustainable Practices in Crypto Mining

Eosinophilic Esophagitis Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, Prevalence, and Companies by DelveInsight

“Eosinophilic Esophagitis Treatment Market”
The Eosinophilic Esophagitis Market size was valued ~ USD 940 thousand million in 2023 and the report offers an in-depth understanding of the Eosinophilic Esophagitis, historical and forecasted epidemiology as well as the Eosinophilic Esophagitis market trends in the 7MM.

(Albany, USA) DelveInsight’s “Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Eosinophilic Esophagitis, historical and forecasted epidemiology as well as the Eosinophilic Esophagitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Eosinophilic Esophagitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Eosinophilic Esophagitis Market Forecast

 

Some of the key facts of the Eosinophilic Esophagitis Market Report: 

  • The Eosinophilic Esophagitis market size was valued approximately USD 940 thousand million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In January 2024, The US FDA granted approval for DUPIXENT (dupilumab) to treat pediatric patients between the ages of 1 and 11 years, weighing at least 15 kg, who have eosinophilic esophagitis (EoE). This approval stems from the Phase III EoE KIDS trial, which demonstrated that a higher percentage of children receiving DUPIXENT achieved histological remission compared to those receiving a placebo.
  • There are few approved medications available in the market to treat eosinophilic esophagitis (EoE), including DUPIXENT (dupilumab) and JORVEZA (budesonide).
  • In 2023, the overall diagnosed prevalent cases of eosinophilic esophagitis (EoE) were estimated to be around 800,000 across the Seven Major Markets (7MM). These numbers are projected to experience moderate growth at a compound annual growth rate (CAGR) by the year 2034.
  • In 2023, within the Seven Major Markets (7MM), the United States reported the highest number of diagnosed prevalent cases of eosinophilic esophagitis (EoE), totaling nearly 500,000 cases.
  • Based on DelveInsight’s analysis, the greatest number of diagnosed cases of eosinophilic esophagitis (EoE) were observed in Germany, with France following closely behind among the EU4 and the UK in 2023. It is anticipated that these numbers will rise throughout the forecast period from 2024 to 2034.
  • According to the National Organisation of Rare Disorders (NORD), 1 in 2,000 people are thought to be affected by eosinophilic esophagitis
  • With 319,429 Eosinophilic Esophagitis cases in 2020, the United States had the most cases among the 7 MM countries
  • Key Eosinophilic Esophagitis Companies: Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Pfizer, Ception Therapeutics, Celgene, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Shire, Novartis, EMS, Celgene, Oxagen Ltd, Meritage Pharma, Inc, Forest Laboratories, and others
  • Key Eosinophilic Esophagitis Therapies: Dupilumab, Cendakimab, APT-1011, Benralizumab, Lirentelimab, ESO-101, Etrasimod, reslizumab, CC-93538, Mesalamine, IRL201104, budesonide, QAX576, Florence, RPC4046, OC000459, Budesonide plus Prevacid, EUR-1100, and others
  • The Eosinophilic Esophagitis epidemiology based on gender analyzed that Eosinophilic Esophagitis affects more males as compared to females
  • The Eosinophilic Esophagitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Eosinophilic Esophagitis pipeline products will significantly revolutionize the Eosinophilic Esophagitis market dynamics.

 

Eosinophilic Esophagitis Overview

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory condition of the esophagus, characterized by the infiltration of eosinophils, a type of white blood cell, into the esophageal lining. This condition is often triggered by food allergens or environmental factors, leading to symptoms such as difficulty swallowing (dysphagia), food impaction, chest pain, and persistent heartburn that does not respond to standard antacid treatments.

Eosinophilic esophagitis is diagnosed through endoscopy and biopsy, where multiple samples of the esophageal tissue are examined for eosinophil infiltration. In adults, EoE can present as intermittent solid food dysphagia and impactions, whereas in children, it might manifest as feeding difficulties, vomiting, and failure to thrive.

Management of Eosinophilic esophagitis involves a combination of dietary modifications, medications, and lifestyle changes. Dietary strategies include elimination diets, where common allergens like dairy, wheat, soy, and nuts are removed, or elemental diets, which use amino acid-based formulas. Medications such as proton pump inhibitors (PPIs) and topical corticosteroids are used to reduce inflammation. In some cases, esophageal dilation may be necessary to alleviate strictures caused by chronic inflammation.

Ongoing research aims to better understand the pathophysiology of Eosinophilic esophagitis and develop more targeted therapies, improving the long-term outcomes and quality of life for individuals affected by this condition.

 

Get a Free sample for the Eosinophilic Esophagitis Market Report: https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market

 

Eosinophilic Esophagitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Eosinophilic Esophagitis Epidemiology Segmentation:

The Eosinophilic Esophagitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Eosinophilic Esophagitis
  • Prevalent Cases of Eosinophilic Esophagitis by severity
  • Gender-specific Prevalence of Eosinophilic Esophagitis
  • Diagnosed Cases of Episodic and Chronic Eosinophilic Esophagitis

 

Download the report to understand which factors are driving Eosinophilic Esophagitis epidemiology trends @ Eosinophilic Esophagitis Prevalence

 

Eosinophilic Esophagitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Eosinophilic Esophagitis market or expected to get launched during the study period. The analysis covers Eosinophilic Esophagitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Eosinophilic Esophagitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Eosinophilic Esophagitis Therapies and Key Companies

  • Dupilumab: Regeneron Pharmaceuticals/Sanofi
  • Cendakimab: Bristol-Myers Squibb
  • APT-1011: Ellodi Pharmaceuticals
  • Benralizumab: AstraZeneca
  • Lirentelimab: Allakos
  • ESO-101: EsoCap AG
  • Etrasimod: Pfizer
  • reslizumab: Ception Therapeutics
  • CC-93538: Celgene
  • Mesalamine: Dr. Falk Pharma GmbH
  • IRL201104: Revolo Biotherapeutics
  • budesonide: Shire
  • QAX576: Novartis
  • Florence: EMS
  • RPC4046: Celgene
  • OC000459: Oxagen Ltd
  • Budesonide plus Prevacid: Meritage Pharma, Inc
  • EUR-1100: Forest Laboratories

 

Discover more about therapies set to grab major Eosinophilic Esophagitis market share @ Eosinophilic Esophagitis Treatment Market

 

Scope of the Eosinophilic Esophagitis Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Eosinophilic Esophagitis Companies: Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Pfizer, Ception Therapeutics, Celgene, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Shire, Novartis, EMS, Celgene, Oxagen Ltd, Meritage Pharma, Inc, Forest Laboratories, and others
  • Key Eosinophilic Esophagitis Therapies: Dupilumab, Cendakimab, APT-1011, Benralizumab, Lirentelimab, ESO-101, Etrasimod, reslizumab, CC-93538, Mesalamine, IRL201104, budesonide, QAX576, Florence, RPC4046, OC000459, Budesonide plus Prevacid, EUR-1100, and others
  • Eosinophilic Esophagitis Therapeutic Assessment: Eosinophilic Esophagitis current marketed and Eosinophilic Esophagitis emerging therapies
  • Eosinophilic Esophagitis Market Dynamics: Eosinophilic Esophagitis market drivers and Eosinophilic Esophagitis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Eosinophilic Esophagitis Unmet Needs, KOL’s views, Analyst’s views, Eosinophilic Esophagitis Market Access and Reimbursement 

 

To know more about Eosinophilic Esophagitis companies working in the treatment market, visit @ Eosinophilic Esophagitis Clinical Trials and FDA Approvals

 

Table of Contents 

1. Eosinophilic Esophagitis Market Report Introduction

2. Executive Summary for Eosinophilic Esophagitis

3. SWOT analysis of Eosinophilic Esophagitis

4. Eosinophilic Esophagitis Patient Share (%) Overview at a Glance

5. Eosinophilic Esophagitis Market Overview at a Glance

6. Eosinophilic Esophagitis Disease Background and Overview

7. Eosinophilic Esophagitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Eosinophilic Esophagitis 

9. Eosinophilic Esophagitis Current Treatment and Medical Practices

10. Eosinophilic Esophagitis Unmet Needs

11. Eosinophilic Esophagitis Emerging Therapies

12. Eosinophilic Esophagitis Market Outlook

13. Country-Wise Eosinophilic Esophagitis Market Analysis (2020–2034)

14. Eosinophilic Esophagitis Market Access and Reimbursement of Therapies

15. Eosinophilic Esophagitis Market Drivers

16. Eosinophilic Esophagitis Market Barriers

17.  Eosinophilic Esophagitis Appendix

18. Eosinophilic Esophagitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Eosinophilic Esophagitis Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, Prevalence, and Companies by DelveInsight

Acquisition of Kadima Neuropsychiatry Institute for CNS & Psychedelic Research Planned; New Drug Application for Treatment of Suicidal Depression: NRx Pharmaceuticals NRXP

$NRXP IS Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression

– Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.

– Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).

– Kadima Neuropsychiatry Institute Targeted as First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics.

– Kadima is a Leading Investigative Site for CNS and Psychedelic Research.

– Completion of NDA Filing Expected in First Quarter of 2025

– Plans to Participate in J.P. Morgan Healthcare Conference on January 13-16, 2025, in San Francisco, CA.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company’s regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100.

Kadima Neuropsychiatry Institute Expected First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics

On January 2nd NRXP announced the planned acquisition of the Kadima Neuropsychiatry Institute of La Jolla, CA, per the previously announced Letter of Intent, for the Company’s HOPE subsidiary network. Kadima is expected to serve as the flagship clinic for HOPE’s planned international network of interventional psychiatry clinics, designed to provide advanced treatments for debilitating diseases such as depression, anxiety and PTSD.

Kadima is one of the world’s premier interventional psychiatry clinics and was among the first to introduce Ketamine Therapy for Central Nervous System (CNS) disorders at scale in the clinic setting. The clinic offers a full range of cutting-edge treatments for suicidal depression, anxiety, Post Traumatic Stress Disorder (PTSD) and other CNS disorders. Those treatment options include Ketamine Therapy, Spravato® (nasal esketamine), Transcranial Magnetic Stimulation as well as medication management.

Kadima also has a robust research division and is a leading investigative site for innovative CNS treatments, specializing in psychedelic research, for which it has served as a leading site in nearly all major clinical trials in this area. Kadima has contracts in place with the US Department of Veterans Affairs and also treats active-duty military personnel in the US Department of Defense under Tricare and other treatment programs.

Kadima’s founder and CEO, Prof. David Feifel, MD PHD, has been a pioneer and international thought leader for advanced interventional treatment of psychiatric disorders such as depression, anxiety, PTSD and related disorders for more than three decades. Among other things, he is a co-author on a recent landmark expert consensus paper for treating depression with TMS, endorsed by three leading organizations in the field (ref). He also established the first clinical program to use subanesthetic dose ketamine infusions for neuropsychiatric disorders at UC San Diego, where he is currently Professor Emeritus of Psychiatry. His 150 peer-reviewed publications and several patents have provided global thought leadership on advanced approaches to treating psychiatric conditions, including integration of medicines like ketamine with neuromodulation such as, Transcranial Magnetic Stimulation and Digital Therapeutics. Kadima’s experience will guide the growing network of NRXP HOPE Therapeutics clinics to an integrated, multi-modal approach to treating suicidal depression, anxiety and PTSD that is far more effective than ketamine alone.

Upon consummation of the proposed acquisition, Dr. Feifel will serve as NRXP HOPE’s Chief Medical Innovation Officer (CMIO), focused on identifying and evaluating new developments in the treatment of CNS disorders and insuring Hope clinics are at the forefront of interventional psychiatry delivery, and leading global clinical trials to continue to advance the ability to treat these lethal diseases.

Dr. Feifel will join NRXP Chairman, Prof. Jonathan Javitt in presenting a Keynote address at the 8th Annual Neuroscience Innovation Forum during the JP Morgan Healthcare Conference in San Francisco, CA on the 12th of January 2025, and will join in meeting investors over the following week.

Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

On December 30th NRXP announced the transmission of first section of its New Drug Application (NDA) for NRX-100 (ketamine) for electronic filing with the U.S. Food & Drug Administration (FDA). NRX-100 was initially granted Fast Track Designation in 2017 for use in combination with NRX-101 (D-cycloserine/lurasidone) for treatment of suicidal bipolar depression. The Company is now seeking to expand the indication to include Suicidal Ideation in Major Depressive Disorder and other forms of depression, based on data from NIH- and European Government-funded trials that have been summarized on the NRXP website.

While assembly of the clinical data sections is being completed, FDA has asked the Company to submit the 1800-page manufacturing section (Module 3) of the NDA to enable immediate review prior to submission of final efficacy data and other sections of the NDA expected in the first quarter of 2025.

The NRx presentation of ketamine differs from the form of ketamine used in anesthesia in that it contains no potentially toxic preservatives and utilizes diversion-resistant packaging to enhance the traceability of a medicine known to have abuse potential.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Disclaimer and Disclosure: www.aibrandnetwork.com

Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: Send Email
Phone: 484 254 6134
Address:1201 Orange Street Suite 600
City: Miami
State: Florida
Country: United States
Website: https://www.nrxpharma.com/

Complicated Urinary Tract Infection (cUTI) Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, Therapies, Companies by DelveInsight

“Complicated Urinary Tract Infection (cUTI) Treatment Market”
Complicated Urinary Tract Infection (cUTI) companies are Pfizer, Novartis, Spero Therapeutics, Tetraphase Pharmaceuticals, Wockhardt, Venatorx Pharmaceuticals, Cubist Pharmaceuticals, Janssen, Allecra Therapeutics, Nabriva Therapeutics AG, La Jolla Pharmaceutical Company, MerLion Pharmaceuticals, PRA Health Sciences, Qilu Pharmaceutical, Meiji Seika Pharma and others.

(Albany, USA) DelveInsight’s “Complicated Urinary Tract Infection (cUTI) Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Complicated Urinary Tract Infection (cUTI), historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection (cUTI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Complicated Urinary Tract Infection (cUTI) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Complicated Urinary Tract Infection (cUTI) market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Complicated Urinary Tract Infection (cUTI) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Complicated Urinary Tract Infection (cUTI) market.

 

Request for a Free Sample Report @ Complicated Urinary Tract Infection (cUTI) Market Forecast

 

Some facts of the Complicated Urinary Tract Infection (cUTI) Market Report are:

  • According to DelveInsight, Complicated Urinary Tract Infection (cUTI) market size is expected to grow at a decent CAGR by 2034.
  • Leading Complicated Urinary Tract Infection (cUTI) companies working in the market are Pfizer, Novartis, Spero Therapeutics, Tetraphase Pharmaceuticals, Wockhardt, Venatorx Pharmaceuticals, Cubist Pharmaceuticals, Janssen, Allecra Therapeutics, Nabriva Therapeutics AG, La Jolla Pharmaceutical Company, MerLion Pharmaceuticals, PRA Health Sciences, Qilu Pharmaceutical, Meiji Seika Pharma and others.
  • Key Complicated Urinary Tract Infection (cUTI) Therapies expected to launch in the market are Ceftazidime –avibactam, Cefepime, LYS228, Eravacycline, Ertapenem, Levofloxacin, CXA-101, TBPM-PI-HBr, Doripenem, Meropenem- FL058, Piperacillin –tazobactam, aztreonam and nacubactam, cefepime and nacubactam, Sulopenem Etzadroxil/Probenecid, Meropenem, Cefepime-zidebactam (FEP-ZID), and others.
  • On June 2023, Meiji Seika Pharma Co announced a Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP).
  • On May 2023, Wockhardt announced a Phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-ZID vs. meropenem in the treatment of hospitalized adults with Complicated Urinary Tract Infection or AP.

 

Complicated Urinary Tract Infection (cUTI) Overview

A complicated urinary tract infection (UTI) refers to an infection that occurs in the urinary tract and is associated with additional factors or conditions that make it more challenging to diagnose, treat, or resolve. These factors can include urinary tract abnormalities, obstruction, kidney stones, immunocompromised state, diabetes, pregnancy, catheterization, or antibiotic resistance. Complicated UTIs may involve not only the lower urinary tract (bladder and urethra) but also the upper urinary tract (kidneys and ureters). The complexity of these infections often necessitates a multidimensional approach, including targeted antibiotic therapy, identification and management of underlying factors, and close monitoring for potential complications.

 

Learn more about Complicated Urinary Tract Infection (cUTI) treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/complicated-urinary-tract-infections-market

 

Complicated Urinary Tract Infection (cUTI) Market 

The Complicated Urinary Tract Infection (cUTI) market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Complicated Urinary Tract Infection (cUTI) market trends by analyzing the impact of current Complicated Urinary Tract Infection (cUTI) therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Complicated Urinary Tract Infection (cUTI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Complicated Urinary Tract Infection (cUTI) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Complicated Urinary Tract Infection (cUTI) market in 7MM is expected to witness a major change in the study period 2020-2034.

 

Complicated Urinary Tract Infection (cUTI) Epidemiology

The Complicated Urinary Tract Infection (cUTI) epidemiology section provides insights into the historical and current Complicated Urinary Tract Infection (cUTI) patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Complicated Urinary Tract Infection (cUTI) market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Complicated Urinary Tract Infection (cUTI) Epidemiology @ Complicated Urinary Tract Infection Prevalence

 

Complicated Urinary Tract Infection (cUTI) Drugs Uptake

This section focuses on the uptake rate of the potential Complicated Urinary Tract Infection (cUTI) drugs recently launched in the Complicated Urinary Tract Infection (cUTI) market or expected to be launched in 2020-2034. The analysis covers the Complicated Urinary Tract Infection (cUTI) market uptake by drugs, patient uptake by therapies, and sales of each drug.

Complicated Urinary Tract Infection (cUTI) Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Complicated Urinary Tract Infection (cUTI) market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Complicated Urinary Tract Infection (cUTI) Pipeline Development Activities

The Complicated Urinary Tract Infection (cUTI) report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Complicated Urinary Tract Infection (cUTI) key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Complicated Urinary Tract Infection (cUTI) pipeline development activities @ https://www.delveinsight.com/sample-request/complicated-urinary-tract-infections-market

 

Complicated Urinary Tract Infection (cUTI) Therapeutics Assessment

Major key companies are working proactively in the Complicated Urinary Tract Infection (cUTI) Therapeutics market to develop novel therapies which will drive the Complicated Urinary Tract Infection (cUTI) treatment markets in the upcoming years are Pfizer, Novartis, Spero Therapeutics, Tetraphase Pharmaceuticals, Wockhardt, Venatorx Pharmaceuticals, Cubist Pharmaceuticals, Janssen, Allecra Therapeutics, Nabriva Therapeutics AG, La Jolla Pharmaceutical Company, MerLion Pharmaceuticals, PRA Health Sciences, Qilu Pharmaceutical, Meiji Seika Pharma and others.

 

Learn more about the emerging Complicated Urinary Tract Infection (cUTI) therapies & key companies @ Complicated Urinary Tract Infection Clinical Trials and FDA Approvals

 

Complicated Urinary Tract Infection (cUTI) Report Key Insights

1. Complicated Urinary Tract Infection (cUTI) Patient Population

2. Complicated Urinary Tract Infection (cUTI) Market Size and Trends

3. Key Cross Competition in the Complicated Urinary Tract Infection (cUTI) Market

4. Complicated Urinary Tract Infection (cUTI) Market Dynamics (Key Drivers and Barriers)

5. Complicated Urinary Tract Infection (cUTI) Market Opportunities

6. Complicated Urinary Tract Infection (cUTI) Therapeutic Approaches

7. Complicated Urinary Tract Infection (cUTI) Pipeline Analysis

8. Complicated Urinary Tract Infection (cUTI) Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Complicated Urinary Tract Infection (cUTI) Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Complicated Urinary Tract Infection (cUTI) Competitive Intelligence Analysis

4. Complicated Urinary Tract Infection (cUTI) Market Overview at a Glance

5. Complicated Urinary Tract Infection (cUTI) Disease Background and Overview

6. Complicated Urinary Tract Infection (cUTI) Patient Journey

7. Complicated Urinary Tract Infection (cUTI) Epidemiology and Patient Population

8. Complicated Urinary Tract Infection (cUTI) Treatment Algorithm, Current Treatment, and Medical Practices

9. Complicated Urinary Tract Infection (cUTI) Unmet Needs

10. Key Endpoints of Complicated Urinary Tract Infection (cUTI) Treatment

11. Complicated Urinary Tract Infection (cUTI) Marketed Products

12. Complicated Urinary Tract Infection (cUTI) Emerging Therapies

13. Complicated Urinary Tract Infection (cUTI) Seven Major Market Analysis

14. Attribute Analysis

15. Complicated Urinary Tract Infection (cUTI) Market Outlook (7 major markets)

16. Complicated Urinary Tract Infection (cUTI) Access and Reimbursement Overview

17. KOL Views on the Complicated Urinary Tract Infection (cUTI) Market

18. Complicated Urinary Tract Infection (cUTI) Market Drivers

19. Complicated Urinary Tract Infection (cUTI) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/medical-devices

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Complicated Urinary Tract Infection (cUTI) Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, Therapies, Companies by DelveInsight